JP7490635B2 - Ｅｇｆｒ変異がんの処置 - Google Patents
Ｅｇｆｒ変異がんの処置 Download PDFInfo
- Publication number
- JP7490635B2 JP7490635B2 JP2021506964A JP2021506964A JP7490635B2 JP 7490635 B2 JP7490635 B2 JP 7490635B2 JP 2021506964 A JP2021506964 A JP 2021506964A JP 2021506964 A JP2021506964 A JP 2021506964A JP 7490635 B2 JP7490635 B2 JP 7490635B2
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- ret
- inhibitor
- pharma
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862717480P | 2018-08-10 | 2018-08-10 | |
| US62/717,480 | 2018-08-10 | ||
| US201862735730P | 2018-09-24 | 2018-09-24 | |
| US62/735,730 | 2018-09-24 | ||
| PCT/US2019/045919 WO2020033838A2 (en) | 2018-08-10 | 2019-08-09 | Treatment of egfr-mutant cancer |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021534129A JP2021534129A (ja) | 2021-12-09 |
| JPWO2020033838A5 JPWO2020033838A5 (https=) | 2022-08-17 |
| JP2021534129A5 JP2021534129A5 (https=) | 2022-08-17 |
| JP7490635B2 true JP7490635B2 (ja) | 2024-05-27 |
Family
ID=69415686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021506964A Active JP7490635B2 (ja) | 2018-08-10 | 2019-08-09 | Ｅｇｆｒ変異がんの処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210308134A1 (https=) |
| EP (1) | EP3833372A4 (https=) |
| JP (1) | JP7490635B2 (https=) |
| CN (1) | CN112703014A (https=) |
| WO (1) | WO2020033838A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| PL3371171T3 (pl) | 2015-11-02 | 2024-03-25 | Blueprint Medicines Corporation | Inhibitory RET |
| SI3773589T1 (sl) | 2018-04-03 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitor RET za uporabo pri zdravljenju raka, ki ima RET spremembo |
| JP2023527412A (ja) | 2020-05-29 | 2023-06-28 | ブループリント メディシンズ コーポレイション | プラルセチニブの固体形態 |
| JP2023501757A (ja) * | 2020-05-29 | 2023-01-18 | ブループリント メディシンズ コーポレイション | プラルセチニブ薬学的組成物 |
| WO2022046867A1 (en) * | 2020-08-25 | 2022-03-03 | Loxo Oncology, Inc. | Osimertinib and selpercatinib combinations for the treatment of egfr- and ret-associated cancers |
| CN116867492A (zh) * | 2020-11-20 | 2023-10-10 | 赫尔森保健股份公司 | 使用4-氨基-n-[4-(甲氧基甲基)苯基]-7-(1-甲基环丙基)-6-(3-吗啉代丙-1-炔-1-基)-7h-吡咯并[2,3-d]嘧啶-5-羧酰胺治疗肿瘤的方法 |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| CN113143931A (zh) * | 2021-04-16 | 2021-07-23 | 南方医科大学 | 甲磺酸奥西替尼在制备寻常型银屑病治疗药物中的应用 |
| CN116440136B (zh) * | 2023-04-17 | 2024-02-09 | 浙江大学智能创新药物研究院 | 甲磺酸阿美替尼在制备治疗乐伐替尼心脏毒性药物中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014525464A (ja) | 2011-09-02 | 2014-09-29 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途 |
| WO2017100642A1 (en) | 2015-12-11 | 2017-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2550361C (en) | 2003-12-19 | 2014-04-29 | Prabha Ibrahim | Compounds and methods for development of ret modulators |
| US20090227598A1 (en) | 2006-01-24 | 2009-09-10 | Buser-Doepner Carolyn A | Ret Tyrosine Kinase Inhibition |
| US20090012045A1 (en) | 2007-06-26 | 2009-01-08 | Rigel Pharmaceuticals, Inc. | Methods of Treating Cell Proliferative Disorders |
| WO2009100536A1 (en) | 2008-02-15 | 2009-08-20 | Methylgene Inc. | Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures |
| EP2740742B1 (en) | 2011-08-04 | 2018-03-14 | National Cancer Center | Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene |
| EP3564261B1 (en) | 2011-08-23 | 2024-11-13 | Foundation Medicine, Inc. | Kif5b-ret fusion molecules and uses thereof |
| JP2015109806A (ja) | 2012-03-22 | 2015-06-18 | アステラス製薬株式会社 | 新規ｒｅｔ融合体の検出法 |
| US20150177246A1 (en) | 2012-07-26 | 2015-06-25 | Lsip, Llc | Fusion gene of cep55 gene and ret gene |
| US20150057335A1 (en) | 2013-08-20 | 2015-02-26 | National Cancer Center | Novel fusion genes identified in lung cancer |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| BR112018000808A2 (pt) | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase |
| CN105255927B (zh) | 2015-09-30 | 2018-07-27 | 温州医科大学附属第一医院 | 一种kiaa1217-ret融合基因 |
| PL3371171T3 (pl) | 2015-11-02 | 2024-03-25 | Blueprint Medicines Corporation | Inhibitory RET |
| TW201738228A (zh) | 2016-03-17 | 2017-11-01 | 藍圖醫藥公司 | Ｒｅｔ之抑制劑 |
| AU2017241837B2 (en) * | 2016-04-01 | 2021-07-22 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
| US10934300B2 (en) | 2017-06-23 | 2021-03-02 | San Diego State University (Sdsu) Foundation | Atropisomerism for enhanced kinase inhibitor selectivity |
| CN109180677A (zh) | 2017-06-30 | 2019-01-11 | 厦门大学 | 取代芳基醚类化合物、其制备方法、药用组合物及其应用 |
| EP3649260B1 (en) | 2017-07-07 | 2022-05-11 | Nipd Genetics Public Company Limited | Target-enriched multiplexed parallel analysis for assessment of tumor biomarkers |
| LT3728271T (lt) | 2017-12-19 | 2022-12-12 | Turning Point Therapeutics, Inc. | Makrocikliniai junginiai, skirti ligų gydymui |
| WO2019143991A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS |
| CN111615514B (zh) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物 |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
-
2019
- 2019-08-09 WO PCT/US2019/045919 patent/WO2020033838A2/en not_active Ceased
- 2019-08-09 EP EP19847106.2A patent/EP3833372A4/en not_active Withdrawn
- 2019-08-09 CN CN201980060618.8A patent/CN112703014A/zh active Pending
- 2019-08-09 JP JP2021506964A patent/JP7490635B2/ja active Active
- 2019-08-09 US US17/267,149 patent/US20210308134A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014525464A (ja) | 2011-09-02 | 2014-09-29 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途 |
| WO2017100642A1 (en) | 2015-12-11 | 2017-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade |
Non-Patent Citations (10)
| Title |
|---|
| Cancer Chemother Pharmacol，2017年，VOl.79，pp.923-932 |
| Cancer Res，2017年，Vol.77, No.13_Supplement，Abstract No.4110 |
| CANCER RESEARCH，2018年07月，Vol.78, No.13_Supplement，Abstract CT043，https://dx.doi.org/10.1158/1538-7445.AM2018-CT043 |
| Journal of Clinical Oncology，2017年，Vol.35, No.15_suppl，Abstract No.11583 |
| JOURNAL OF CLINICAL ONCOLOGY，2018年03月20日，Vol.36, No.9，pp.841-849，https://ascopubs.org/doi/10.1200/JCO.2017.74.7576 |
| Journal of Thoracic Oncology，2018年04月，Vol.13, No.4，pp.e49-e53 |
| Lancet Oncol，2016年，Vol.17，pp.1661-1671 |
| LUNG CANCER，2015年09月，Vol.89, No.3，pp.357-359，https://dx.doi.org/10.1016/j.lungcan.2015.06.021 |
| Nature Genetics，2012年，Vol.44, No.8，pp.852-860 |
| Nature Reviews Clinical Oncology，2018年03月，Vol.15，pp.151-167 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3833372A4 (en) | 2022-06-08 |
| CN112703014A (zh) | 2021-04-23 |
| WO2020033838A2 (en) | 2020-02-13 |
| US20210308134A1 (en) | 2021-10-07 |
| WO2020033838A3 (en) | 2020-03-19 |
| EP3833372A2 (en) | 2021-06-16 |
| JP2021534129A (ja) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7490635B2 (ja) | Ｅｇｆｒ変異がんの処置 | |
| Fu et al. | Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance | |
| JP7712990B2 (ja) | 血小板由来成長因子受容体アルファの遺伝的異常に関連する癌の治療のための、１－［４－ブロモ－５－［１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル］－２－フルオロフェニル］－３－フェニルウレアおよびアナログの使用 | |
| KR20210126653A (ko) | Tno155 및 리보시클립을 포함하는 약제학적 조합물 | |
| EP3453392B1 (en) | Therapeutic agent for lung cancer that has acquired egfr-tki resistance | |
| JP2022034068A (ja) | 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物 | |
| KR20250027777A (ko) | 암을 치료하기 위한 kras g12c 억제제 | |
| KR20240000534A (ko) | Raf 억제제를 이용하는 암의 치료 | |
| JP2020519672A (ja) | ＲＥＴ阻害剤とｍＴＯＲＣ１阻害剤との組合せ及び異常なＲＥＴ活性によって媒介されるがんを処置するためのその使用 | |
| CN106211755A (zh) | 使用erk和raf抑制剂的组合的癌症治疗 | |
| US20140024030A1 (en) | Preselection of subjects for therapeutic treatment with oxygen sensitive agents based in hypoxic status | |
| TW201032796A (en) | Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor | |
| JP2023165937A (ja) | Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 | |
| KR20220024540A (ko) | 암 환자에서의 항종양 면역의 증진을 위한 환자 선택 | |
| CN113164415A (zh) | 依拉司群和阿贝西利在患乳腺癌女性中的联合应用 | |
| JP2023524789A (ja) | Ｔｎｏ１５５及びナザルチニブを含む医薬組合せ | |
| JP2024528705A (ja) | がんのための治療としてのクレアチン輸送を阻害するための組成物及び方法 | |
| JP2022533100A (ja) | Ｎｏｔｃｈ活性化乳がんを治療するためのビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物 | |
| WO2023049363A1 (en) | Sotorasib and afatinib for treating cancer comprising a kras g12c mutation | |
| KR20210145161A (ko) | Her2 엑손 21 삽입물을 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 | |
| JP2022515128A (ja) | がんの処置のための併用療法 | |
| US11957677B2 (en) | Cancer treatment using FGFR inhibitors and PLK1 inhibitors | |
| HK40044366A (en) | Treatment of egfr-mutant cancer | |
| WO2025201518A1 (en) | Methods of treating tki-resistant and sdh-deficient gist | |
| HK40124174A (zh) | Blu-945联合奥斯替尼治疗非小细胞肺癌 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220808 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220808 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230830 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240124 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240425 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240515 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7490635 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S801 | Written request for registration of abandonment of right |
Free format text: JAPANESE INTERMEDIATE CODE: R311801 |
|
| ABAN | Cancellation due to abandonment | ||
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |